Medical Oncology

, Volume 23, Issue 1, pp 91–104

Advanced colon cancer

Antiprogressive immunotherapy using an autologous hemoderivative


    • Research & Development DepartmentPharmaBlood Inc
    • National Institute of Oncology
  • Emilio Garcia-Giralt
    • Centre De Cancerologie Hartmann
  • Silvia Cucchi
    • Department of Advanced Medical Treatments
  • Jesús Vázquez
    • Department of Advanced Medical Treatments
    • National Institute of Oncology
  • Eduardo Lasalvia-Galante
    • Department of Advanced Medical Treatments
  • Wilson Golomar
    • Department of Advanced Medical Treatments
    • National Institute of Oncology
  • Joshemaria Larrañaga
    • Department of Advanced Medical Treatments
    • National Institute of Oncology
Original Article

DOI: 10.1385/MO:23:1:91

Cite this article as:
Lasalvia-Prisco, E., Garcia-Giralt, E., Cucchi, S. et al. Med Oncol (2006) 23: 91. doi:10.1385/MO:23:1:91



Advanced colon cancer patients, acquired-chemotherapy resistant and in progression, are therapeutically terminal. We tested a recently described medical procedure using a thermostable autologous hemoderivative purported to inhibit tumor growth possibly through an immunological mechanism of action.

Patients and Methods

Metastatic colon cancer patients chemotherapy-resistant, high CEA plasma levels, in progression, were 2-group randomized. Group 1 received the test procedure and Group 2 adequate control measures. During an 8-mo follow-up period (n=101), tumor growth, number of cases attaining clinical nonprogressive status, and mortality were assessed monthly. Immunological effect was assessed by delayed-type hypersensitivity test and lymphocyte proliferation assay. Responding-tumors histopathologies were studied.

Results and Discussion

In a significant number of cases, the test procedure promoted inhibition of tumor growth, nonprogressive disease status, and lower cumulative mortality. These clinical results were associated with polyvalent immunization against several tested antigens: the hemoderivative used for treatment, the blood tumor markers, and the regulatory lymphocyte population (CD4+CD25+). Interference with this regulatory activity could explain the selective autoimmunity suggested by the histopathology findings in responding tumors.


The autologous hemoderivative tested is antigenically polyvalent and promotes a polytargeted immune response associated with a tumor antiprogressive effect, consequently, acting as an autologous hemoderivative cancer vaccine.

Key words

Autologous hemoderivativecolon cancervaccine

Copyright information

© Humana Press Inc. 2006